The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Epioxa Cross-Linking
riboflavin 5-phosphate ophthalmic · Kit · Ophthalmic · Glaukos Corporation
NDC 25357-0024-01 · 1 KIT in 1 CARTON * 1 SYRINGE, GLASS in 1 POUCH / 2 mL in 1 SYRINGE, GLASS * 1 SYRINGE, GLASS in 1 POUCH / 2 mL in 1 SYRINGE, GLASS · NDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Regulatory
- Application
- NDA219910
- TE code
- —
- Approval date
- Oct 17, 2025
- Patents / exclusivity
- 0 patents, 1 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| exclusivity | NP | Oct 17, 2028 |
Shortage history
- Planned discontinuation — Photrexa Cross-linking Kit, Ophthalmic Solution, Kit (NDC 25357-025-03)Jan 20, 2026
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of riboflavin 5-phosphate ophthalmic (Kit)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Glaukos Corporation | Jul 15, 2026 | Aug 31, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Epioxa Cross-Linking — NDC 25357-0024-01," retrieved September 3, 2026, https://drugdashboards.com/drug/25357002401.
Free to cite with attribution — see how the data is put together.